GlassScriptPhysician profile
Verna Broughton
NPI 1245388925
$9,214.78
in general payments reported to CMS, 2019-2025
25 companies · $1,461 in 2025
The $1,461 reported for 2025 was more than what 87% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,314 · 2022: $1,582 · 2023: $2,152 · 2024: $2,704 · 2025: $1,461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,052 · Consulting Fee: $1,000 · Education: $266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,052.02 |
| Consulting Fee | $1,000.00 |
| Education | $266.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medimetriks Pharmaceuticals, INC. | $1,269.47 | 2022-2024 | Neo-Synalar, Clindacin Etz, Neuac |
| Pfizer INC. | $939.84 | 2021-2025 | |
| Leo Pharma INC. | $862.07 | 2021-2025 | Adbry, Anzupgo |
| Abbvie INC. | $830.80 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $731.54 | 2021-2025 | |
| Janssen Biotech, INC. | $682.92 | 2022-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $606.25 | 2021-2025 | Ilumya |
| Regeneron Healthcare Solutions, INC. | $472.62 | 2021-2025 | Dupixent |
| Ucb, INC. | $377.00 | 2023-2025 | Bimzelx, Cimzia |
| Dermavant Sciences, INC. | $336.26 | 2023-2024 | Vtama |
| Lilly USA, LLC | $299.62 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $287.53 | 2021-2025 | Duobrii, Jublia, Siliq |
| Arcutis Biotherapeutics, INC. | $282.03 | 2023-2025 | Zoryve |
| Incyte Corporation | $262.19 | 2022-2025 | Opzelura |
| Genzyme Corporation | $235.95 | 2021-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $190.86 | 2021-2025 | Nemluvio, Aklief |
| Mayne Pharma Commercial LLC | $126.07 | 2021-2025 | |
| Vyne Pharmaceuticals INC. | $79.50 | 2021 | |
| Epi Health, LLC | $77.35 | 2021-2022 | |
| Organon LLC | $72.15 | 2025 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $64.00 | 2022-2024 | Sotyktu |
| Amgen INC. | $51.20 | 2022-2025 | Otezla |
| Almirall LLC | $31.18 | 2021-2022 | |
| Allergan, INC. | $26.60 | 2021 | |
| Phadia US INC. | $19.78 | 2023 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Verna Broughton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.